TY  - JOUR
AU  - Leiter, L A
AU  - Tinahones, F J
AU  - Karalis, D G
AU  - Bujas-Bobanovic, M
AU  - Letierce, A
AU  - Mandel, J
AU  - Samuel, R
AU  - Jones, P H
PY  - 2018
DO  - 10.1111/dme.13817
UR  - http://hdl.handle.net/10668/12906
T2  - Diabetic medicine : a journal of the British Diabetic Association
AB  - To evaluate the safety of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor alirocumab according to diabetes mellitus status. Safety data from 14 trials (8-104-week durations) were analysed by treatment (alirocumab or...
LA  - en
PB  - Wiley
KW  - Diabetes complications
KW  - Diabetes mellitus
KW  - Heart diseases
KW  - Hypercholesterolemia
KW  - PCSK9 Inhibitors
KW  - Aged
KW  - Antibodies, monoclonal
KW  - Antibodies, monoclonal, humanized
KW  - Clinical trials, phase II as topic
KW  - Clinical trials, phase III as topic
KW  - Diabetes complications
KW  - Diabetes mellitus
KW  - Drug-related side effects and adverse reactions
KW  - Female
KW  - Heart diseases
KW  - Humans
KW  - Hypercholesterolemia
KW  - Incidence
KW  - Male
KW  - Middle aged
KW  - PCSK9 Inhibitors
KW  - Proprotein convertase 9
KW  - Randomized controlled trials as topic
TI  - Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials.
TY  - research article
VL  - 35
ER  -